Kosheeka’s Post

𝐌𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 💉🧬 - 🎯 Targeted Therapy: Monoclonal antibodies (mAbs) precisely target cancer cells, reducing collateral damage to healthy cells. - 🛡️ Immune System Boost: Some mAbs enhance the body’s immune response, helping it recognize and destroy cancer cells more effectively. - 🧪 Combination Potential: They can be combined with chemotherapy and radiotherapy, improving the overall efficacy of cancer treatment protocols. - 📊 Clinical Success: Multiple mAbs have gained FDA approval, showcasing their proven success in treating various types of cancer, such as HER2-positive breast cancer and non-Hodgkin lymphoma. Explore more insightful reviews on pioneering biomedical research at sciqst.com! 🔬✨ #CancerResearch #Biotechnology #Immunotherapy #MonoclonalAntibodies

Summary: The research explores using chromium-based nanocomposites for cancer therapy, focusing on enhancing CAR-T cell infiltration and cytotoxicity against solid tumors. The study demonstrates that these nanocomposites, when combined with polydopamine and the anticancer drug alpelisib, can improve CAR-T cell migration and antitumor efficacy through inducing mild hyperthermia in the tumor microenvironment, leading to tumor growth inhibition and increased cytokine secretion. Hashtags: #CancerTherapy #CAR-TCells #Nanocomposites #TumorMicroenvironment #Biohacking Tip: Optimize your cancer treatment strategy by exploring innovative approaches such as combining nanocomposites with immunotherapy to enhance the effectiveness of CAR-T cell therapy against solid tumors. Stay informed about the latest advancements in cancer research to make informed decisions about your treatment plan. Read more here: https://lnkd.in/djzaiaww BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

🔬 Innovative Immunotherapy Breakthrough: Researchers at Virginia Tech Virginia State University have developed a new technique using particle-bound cytokines to enhance cancer immunotherapy. 🌟 Published Findings: Their study, featured in Science Advances, demonstrates how cytokines tethered to microparticles localize within tumors, improving efficacy while minimizing systemic exposure. 🧬 Combination Therapy: By combining particle-anchored cytokines with immune checkpoint blockade (ICB), researchers observed tumor regression and systemic antitumor immunity in multiple mouse models. 💡 Key Insight: "Our approach activates immune cells within tumors while sparing healthy cells," explained research co-lead Dr. Rong Tong. This strategy enhances cancer treatment effectiveness and safety. 🩺 Promising Future: This novel technique could revolutionize cancer immunotherapy by delivering potent cytokines directly to tumors, minimizing side effects. #Immunotherapy #CancerResearch #ParticleTherapy #ScienceAdvances #TumorTreatment #InnovativeResearch #VirginiaTechResearch #MedicalBreakthrough #CytokineTherapy #ImmunostimulatoryAgents #CombinationTherapy #CancerImmunotherapy #medicalresearchnews

Recent advances in immunotherapy and its combination therapies for advanced melanoma were reviewed in this article, highlighting the increasing incidence of melanoma and the importance of effective treatments for this highly malignant cancer. Immunotherapies such as immune checkpoint inhibitors, bispecific antibodies, and adoptive cell transfer therapy, along with innovative combination approaches, including immunotherapy with radiotherapy, have shown promising outcomes in the treatment of advanced melanoma. The continuous progress and evolution of these treatment modalities offer new strategies and hope for patients battling this aggressive form of cancer. #MelanomaTreatment #ImmunotherapyAdvances #CombinationTherapies #CancerResearch #InnovativeTreatmentOptions Read more here: https://lnkd.in/eam6fHPw BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

https://lnkd.in/eUNz2Z7y). The dual role of complement in cancer and its implication in anti-tumor therapy

#cancerresearch #oncology #cancertreatment #immunology #immunotherapy https://lnkd.in/eMMVBPe8 #mRNA has the potential to encode both vaccines and immunomodulatory proteins for cancer immunotherapy. In this issue, Beck et al. report on lipopolyplexed mRNAs encoding albumin-stabilized interleukin-2 to transduce #liver #cells. These mRNAs attain antitumor efficacy on subcutaneous mouse tumors even if malignant cells lack major histocompatibility complex class I (MHC class I) expression.

Latest issue!🏹 #𝐆𝐚𝐥𝐞𝐜𝐭𝐢𝐧-𝟑 𝐚𝐧𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 #𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲: 𝐚 𝐠𝐥𝐲𝐜𝐨𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐫𝐚𝐭𝐢𝐨𝐧𝐚𝐥𝐞 𝐭𝐨 𝐨𝐯𝐞𝐫𝐜𝐨𝐦𝐞 𝐭𝐮𝐦𝐨𝐫 𝐢𝐦𝐦𝐮𝐧𝐞 𝐞𝐬𝐜𝐚𝐩𝐞 -------------------------- Immunotherapy with checkpoint inhibitors (ICIs) has radically changed the landscape of therapeutic opportunities in oncology, but much still needs to be understood from a mechanistic point of view. There is space for further improving tumors’ response to ICIs, as supported by a strong biological rationale. For this achievement a detailed analysis of tumor cell phenotype with functional dissection of the molecular interactions occurring in the TME is required. Galectin-3 is a pleiotropic tumor relevant molecule, which deserves particular attention in immuno-oncology. Due to its ability to finely modulate immune response in vivo, Galectin-3 is a potential target molecule to be considered for overcoming tumor immune escape. Read here this interesting Commentary by Armando Bartolazzi, Giorgia Scafetta and Calogero D'Alessandria 👇 https://lnkd.in/d_udu_YQ #CheckpointInhibitors #TumorMicroenvironment IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Targeting Galectin-1 in prostate cancer can improve the effectiveness of immunotherapy by reducing T cell apoptosis in the tumor microenvironment. Inhibitors like LLS30 can enhance intratumoral T cell infiltration, boosting the antitumor response and synergizing with existing treatments. Consider exploring the potential benefits of Galectin-1 inhibition to enhance immune response in prostate cancer. #ProstateCancer #Immunotherapy #TumorMicroenvironment #Galectin1 #LLS30 BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X. Read more about this post here: https://lnkd.in/eghCy6-Z

🚀 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲! 🧬 Discoveries in virus-specific tumor-infiltrating T cells (TBYS cells) are shaping innovative cancer treatments. Studies show TBYS cells mimic memory T cells, aiding in targeted therapies like NDV-GP and Ad5-GP. These therapies boost immune cell responses in the tumor microenvironment, with CD8+ and CD4+ TBYS cells playing vital roles. Recent findings also highlight the cytotoxic potential of CD4+ TBYS cells, offering new avenues for anti-tumor strategies. Stay informed on cutting-edge cancer immunotherapy developments! #CancerResearch #ImmunotherapyBreakthroughs 🌟🔬

Great insights from Dr. Kristina Young’s talk on targeting #TGF-β in rectal cancer, showing that TGF-β directly impact #CD8+ T-cells anti-tumor efficacy ⁉ TGF-β plays a complex role in tumorigenesis, acting as an immunosuppressive cytokine. Blocking TGF-β improves radiation response in a CD8+ T cell-dependent manner. 👨⚕️ In a clinical #trial with galunisertib (TGF-β inhibitor), 38 patients saw promising results: 12 complete responses with minimal adverse events. 💉 Peripheral immune monitoring showed early lymphocyte drop and a loss of activated CD8+ memory T cells, surprisingly correlated with therapy response. 🥊 Knockout mice studies (Alk5 KO) revealed increased tumor-infiltrating T cells and enhanced CD8+ effector functions, linked to CXCR3 expression, which is repressed by TGF-β. #Immunotherapy #TGFBeta #RectalCancer #OncologyResearch #CD8TCells